Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 par value per share
-
Shares outstanding
-
73.8M
-
Number of holders
-
87
-
Total 13F shares, excl. options
-
15M
-
Shares change
-
-1.09M
-
Total reported value, excl. options
-
$45M
-
Value change
-
-$3.17M
-
Put/Call ratio
-
2.25
-
Number of buys
-
19
-
Number of sells
-
-52
-
Price
-
$3.00
Significant Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) as of Q3 2023
104 filings reported holding RLMD - RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share as of Q3 2023.
RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) has 87 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15M shares
of 73.8M outstanding shares and own 20.31% of the company stock.
Largest 10 shareholders include Deep Track Capital, LP (2.84M shares), RTW INVESTMENTS, LP (2.13M shares), VANGUARD GROUP INC (1.31M shares), ACADIAN ASSET MANAGEMENT LLC (1.17M shares), PARSONS CAPITAL MANAGEMENT INC/RI (974K shares), Palo Alto Investors LP (732K shares), BlackRock Inc. (574K shares), CITADEL ADVISORS LLC (432K shares), Mirae Asset Global Investments Co., Ltd. (259K shares), and MILLENNIUM MANAGEMENT LLC (244K shares).
This table shows the top 87 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.